Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Status:
NOT_YET_RECRUITING
Trial end date:
2030-11-30
Target enrollment:
Participant gender:
Summary
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.